Tevimbra — Tislelizumab
Tislelizumab is an anti-PD-1 checkpoint inhibitor engineered specifically to reduce a binding interaction linked to reduced immunotherapy effectiveness in other PD-1 drugs — a design choice reflected in its particularly strong clinical trial performance in esophageal squamous cell carcinoma, a cancer with disproportionately high incidence across parts of Southeast Asia. This makes it a strategically important product for that specific export corridor, beyond its broader oncology approval base.
- Approved indications: Classical Hodgkin lymphoma, non-small cell lung cancer, hepatocellular (liver) carcinoma, esophageal squamous cell carcinoma
- Mechanism: Blocks PD-1, restoring immune-cell ability to recognize and attack cancer cells, with an engineered Fc region designed to minimize macrophage-mediated T-cell depletion
- Standout clinical data: Particularly strong efficacy signal in esophageal squamous cell carcinoma, a cancer type with high regional prevalence in China and parts of Southeast Asia
- Typical use case: Often used after other treatment lines have been exhausted, though increasingly moving into earlier lines of therapy as clinical evidence expands
Key Product Facts
100mg
Strength
Single-dose vial
Pack Size
Tislelizumab
Active Ingredient
Oncology
Category
On Request
Availability
Tislelizumab is an anti-PD-1 checkpoint inhibitor engineered specifically to reduce a binding interaction linked to reduced immunotherapy effectiveness in other PD-1 drugs — a design choice reflected in its particularly strong clinical trial performance in esophageal squamous cell carcinoma, a cancer with disproportionately high incidence across parts of Southeast Asia. This makes it a strategically important product for that specific export corridor, beyond its broader oncology approval base.
- Approved indications: Classical Hodgkin lymphoma, non-small cell lung cancer, hepatocellular (liver) carcinoma, esophageal squamous cell carcinoma
- Mechanism: Blocks PD-1, restoring immune-cell ability to recognize and attack cancer cells, with an engineered Fc region designed to minimize macrophage-mediated T-cell depletion
- Standout clinical data: Particularly strong efficacy signal in esophageal squamous cell carcinoma, a cancer type with high regional prevalence in China and parts of Southeast Asia
- Typical use case: Often used after other treatment lines have been exhausted, though increasingly moving into earlier lines of therapy as clinical evidence expands
- Pregnancy/breastfeeding: Unsafe — effective contraception advised for at least 4 months following the final dose
- Immune-related risk: Pneumonitis, hepatitis, and thyroid dysfunction possible, requiring ongoing monitoring throughout treatment
- Vaccination: Live vaccines should be avoided during active treatment
- Monitoring cadence: Baseline and periodic thyroid function, liver function, and pulmonary assessment recommended
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| Free Sale Certificate (FSC) |
? Standard |
| MSDS |
? Standard |
Stock status: In stock for export | Quote turnaround: 24 hours
- Logistics: GDP-compliant cold-chain export
- Coverage: Global, with a particularly strong and growing Southeast Asia corridor
- Tracking: Full shipment tracking included
What is Tislelizumab used for?
Treats Hodgkin lymphoma, lung cancer, liver cancer, and esophageal cancer by helping the immune system attack tumor cells.
Get Tislelizumab price from a GMP-compliant Indian pharmaceutical supplier and exporter for cancer treatment in your country — how?
Send strength and destination for a verified quote. Request availability today.
Why is it particularly relevant for esophageal cancer?
It has shown especially strong clinical data in esophageal squamous cell carcinoma, a cancer with high incidence in parts of Asia.
Who supplies Tislelizumab from India?
WHO-GMP certified manufacturing partners with full documentation.
Is it chemotherapy?
No, it's an immune checkpoint inhibitor that works differently from chemotherapy by activating the immune system.
